HER-2 and ER expression in prediction of chemo-sensitivity of taxane for advanced breast cancer.
- Author:
Fang LIU
1
;
Ze-Fei JIANG
;
San-Tai SONG
;
Jun-Zhong SUN
;
Shao-Hua ZHANG
;
Sheng-Qiang FENG
Author Information
- Publication Type:Journal Article
- MeSH: Antineoplastic Agents, Phytogenic; therapeutic use; Breast Neoplasms; drug therapy; metabolism; pathology; Female; Humans; Immunohistochemistry; Multivariate Analysis; Neoplasm Staging; Paclitaxel; therapeutic use; Predictive Value of Tests; Prognosis; Receptor, ErbB-2; metabolism; Receptors, Estrogen; metabolism; Remission Induction; Retrospective Studies; Taxoids; therapeutic use
- From: Chinese Journal of Oncology 2006;28(6):449-451
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo investigate the predictive value of HER-2 and ER expression for chemosensitivity of taxane in the treatment of advanced breast cancer.
METHODSOf 268 advanced breast cancer patients treated: 71 were by paclitaxel alone, 32 by docetaxel alone, 110 by paclitaxel combined with anthracylines or gemcitabine or platins and 55 by docetaxel-based combinations. HER-2 and ER expression of all patients treated by taxane underwent immunohistochemical (IHC) assay.
RESULTSUnivariate analysis showed: the response rate (RR) in HER-2 overexpression group was 56.7%, and in HER-2 weak expression group 33.3% (P = 0.003). The response rate in ER positive group and ER negative group was 33.3% and 48.9%, respectively, with a significant difference (P = 0.015). The RR was 67.6% in ER negative but HER-2 overexpression group. However, in ER positive but HER-2 weak expression group and the other groups, the RR were around 35% (P < 0. 01). Multivariate analysis showed that overexpression of HER-2 was the only significant factor to predict the chemosensitivity of taxane (P = 0. 007), but the ER, Karnofsky performance score (KPS), anthracylines, metastatic sites were not the statistically significant chemo-sensitivity predictive factors for taxane.
CONCLUSIONER negative and/or HER-2 overexpression, especially latter, may be associated with good response in advanced breast cancers treated by taxane.
